Gene expression profiles in human autoimmune disease

Current Pharmaceutical Design

Volumn 9, Issue 23, 2003, Pages 1905-1917

  Aune, Thomas M ^a   Maas, Kevin ^a   Moore, Jason H ^a   Olsen, Nancy J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 6; ENDOGLIN; EPOXIDE HYDROLASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MONOPHENOL MONOOXYGENASE; MYOSIN; PROTEIN C FOS; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN P27; PROTEIN P53; UBIQUINONE; UVOMORULIN;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLUSTER ANALYSIS; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC CODE; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; SIGNAL TRANSDUCTION;

EID: 0042976370     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454360     Document Type: Review

References (39)

1. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223-43.
2. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev 1996; 17: 369-84.
3. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001; 44: 1234-6.
4. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999; 78: 167-75.
5. Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J. Rheumatol 2001; 28: 1718-22.
6. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 1989; 83: 1267-76.
7. Yamanishi Y, Boyle DL, Pinkoski MJ, Mahboubi A, Lin T, Han Z, et al. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 2002; 160: 123-30.
8. Firestein GS Echeverri F Yeo M Zvaifler NJ Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997; 94: 10895-900.
9. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180: 341-6.
10. Berse B, Hunt JA, Diegel RJ, Morganelli P, Yeo K, Brown F, et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999 115: 176-82.
11. Kaltenhauser S, Wagner U, Schuster E, Wassmuth R, Arnold S, Seidel W, et al. Immunogenetic markers and seropositivity predict radiological progression in early rheumatoid arthritis independent of disease activity. J.Rheumatol 2001; 28: 735-44.
12. Pascual M, Mataran L, Jones G, Shing D, van der Slik AR, Giphart MJ, et al.. HLA haplotypes and susceptibility to rheumatoid arthritis. More than class II genes. Scand J Rheumatol 2002; 31: 275-8.
13. Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998; 95: 9979-84.
14. Lin JP, Cash JM, Doyle SZ, Peden S, Kanik K, Arnos CI, et al. Familial clustering of rheumatoid arthritis with other autoimmune diseases. Hum Genet 1998; 103: 475-82.
15. Cohen MG, Webb J. Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis 1987; 46: 853-8.
16. Edberg JC, Langefeld CD, Wu J, Moser KL, Kaufman KM, Kelly J, et al. Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2132-40.
17. Namjou B, Nath SK, Kilpatrick J, Kelly JA, Reid J, James JA, et al. Stratification of pedigrees multiplex for systemic lupus erythematosus and for self-reported rheumatoid arthritis detects a systemic lupus erythematosus susceptibility gene (SLER1) at 5p15.3. Arthritis Rheum 2002; 46: 2937-45.
18. Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N, et al. Cutting Edge: Molecular portrait of human autoimmune disease. J Immunol 2002; 169: 5-9.
19. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-8.
20. Sherlock G. Analysis of large-scale gene expression data. Curr Opin Immunol 2000; 12: 201-5.
21. Krichevsky AM, Metzer E, Rosen H. Translational control of specific genes during differentiation of HL-60 cells. J Biol Chem 1999; 274: 14295-305.
22. Rosen A, Casciola-Rosen L. Clearing the way to mechanisms of autoimmunity. Nat Med 2001; 7: 664-5.
23. Ravirajan CT, Pittoni V, Isenberg DA. Apoptosis in human autoimmune diseases. Int Rev Immunol 1999; 18: 563-89.
24. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39-43.
25. Zhang J, Bardos T, Mikecz K, Finnegan A, Glant TT. Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune murine arthritis. J Immunol 2001; 166: 4981-6.
26. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996; 98: 1107-13.
27. Jackson CE, Fischer RE, Hsu AP, Anderson SM, Choi Y, Wang J, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet 1999; 64: 1002-14.
28. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 1999; 130: 591-601.
29. Balomenos D, Martinez AC. Cell-cycle regulation in immunity, tolerance and autoimmunity. Immunol Today 2000; 21: 551-5.
30. Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass I, Blazar BR, et al. p27 kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 2000; 6: 290-7.
31. Balomenos D, Martin-Caballero J, Garcia MI, Prieto I, Flores JM, Serrano M, et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 2000; 6: 171-6.
32. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001; 7: 899-05.
33. Bias WB, Reveille JD, Beaty TH, Meyers DA, Arnett FC. Evidence that autoimmunity in man is a Mendelian dominant trait. Am J Hum Genet 1986; 39: 584-02.
34. Amundson SA, Myers TG, Fornace AJ, Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 1998; 17: 3287-98.
35. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes and Devel 2000; 14: 981-92.
36. Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001; 20: 3449-58.
37. Alarcon de la Lastra C, Barranco MD, Motilva V, Herrerias JM. Mediterranean diet and health: biological importance of olive oil. Curr Pharm Des 2001-1 7(10): 933-50.
38. Aloe L, Tirassa P, Bracci-Laudiero L. Nerve growth factor in neurological and non-neurological diseases: basic findings and emerging pharmacological prospectives. Curr Pharm Des 2001; 7(2): 113-23.
39. Ito C. Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia. Curr Pharm Des 2002; 8(2): 147-53.